Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBQZ2H)

• Drug Name: [3H]rauwolscine Drug Info
• Synonyms: Rauwolscine; alpha-Yohimbine; Mesoyohimbine; Isoyohimbine; Corynanthidine; 131-03-3; UNII-T4LJ7LU45W; Methyl (16beta,17alpha,20alpha)-17-hydroxyyohimban-16-carboxylate; T4LJ7LU45W; CHEMBL10347; CHEBI:48562; 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylic acid methyl ester; NCGC00017260-05; methyl 17alpha-hydroxy-20alpha-yohimban-16beta-carboxylate; 17-alpha-Hydroxy-20-alpha-yohimban-16-beta-carboxylic acid methyl ester; EINECS 205-006-9; 20-alpha-Yohimban-16-beta-carboxylic acid, 17-alpha-hydroxy-, methyl ester

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 643606
  ChEBI ID: CHEBI:48562
  CAS Number: CAS 131-03-3
  TTD Drug ID: DMBQZ2H

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor alpha-2C (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[5]
Dihydroergocristine	DM5SQ1G	Alcohol dependence	6C40.2	Approved	[6]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[7]
Amosulalol	DML8QSZ	Hypertension	BA00-BA04	Approved	[8]
Amezinium	DM6I2WQ	Hypotension	BA20-BA21	Approved	[9]
Propylhexedrine	DMTBW2O	Obesity	5B81	Approved	[10]
Tetrahydrozoline	DMT57WC	Ocular disease	1F00.1Z	Approved	[11]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[12]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[13]
TNX-102	DMO1234	Fibromyalgia	MG30.01	Phase 3	[14]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[15]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[16]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[17]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[18]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[19]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[20]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[21]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[21]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[21]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[21]

Drug(s) Targeting Adrenergic receptor Alpha-2 (ADRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[22]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[23]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[24]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[22]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[25]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[26]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[27]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[28]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[29]
Oxymetazoline	DM8ZXT6	Arrhythmia	BC9Z	Approved	[30]

Drug(s) Targeting Adrenergic receptor alpha-2B (ADRA2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MOXONIDINE	DMGFB0E	Alcohol dependence	6C40.2	Approved	[5]
MEDETOMIDINE	DMX9Y7V	Pain	MG30-MG3Z	Phase 2	[31]
AGN-199981	DMP5Y1A	Neuropathic pain	8E43.0	Phase 2	[32]
INDORAMIN	DMNSJFD	Hypertension	BA00-BA04	Withdrawn from market	[33]
MAZAPERTINE	DMRHYAU	N. A.	N. A.	Discontinued in Phase 2	[34]
SNAP-5089	DMROJEN	Heart arrhythmia	BC65	Terminated	[35]
A-80426	DMBC3DG	N. A.	N. A.	Terminated	[36]
WB-4101	DMQU8B1	N. A.	N. A.	Terminated	[37]
SK&F-104078	DMRADBU	N. A.	N. A.	Terminated	[33]
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Antagonist	[2]
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Antagonist	[3]
Adrenergic receptor alpha-2B (ADRA2B)	TTWM4TY	ADA2B_HUMAN	Antagonist	[4]
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Antagonist	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 223).
• [2] [3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24.
• [3] Characterization of alpha-adrenoceptor subtypes in smooth muscle of equine ileum. Am J Vet Res. 2001 Sep;62(9):1370-4.
• [4] Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992 Jul;42(1):1-5.
• [5] Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
• [6] Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7.
• [7] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
• [8] Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5.
• [9] Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65.
• [10] Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7.
• [11] Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2.
• [12] Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50.
• [13] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [14] Clinical pipeline report, company report or official report of Tonix Pharmaceuticals.
• [15] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [16] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [17] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [18] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [19] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [20] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [21] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [22] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [23] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [24] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [25] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [26] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [27] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [28] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [29] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [30] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
• [31] A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
• [32] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [33] Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44.
• [34] A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
• [35] Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
• [36] Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
• [37] alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401.
• [38] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.